Stock Ratings / Health Care / MDXG / earnings

TCMD (67) SGHT (39) ANGO (36) SENS (40) ⌘ Pro Terminal →

MiMedx Group Inc (MDXG) Next Earnings Date & Expected ±10.2% Move

$3.88 -2.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.86

MiMedx Group Inc (MDXG) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $566.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDXG Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, MiMedx Group Inc (NASDAQ: MDXG) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $3.88 (-2.27% 1D, market cap $566.2M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 19/20. Across 1016 tracked Health Care issuers, MDXG ranks #86 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MDXG compare to TCMD and SGHT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), MDXG carries a Roarable C+ (69/100 RQD), trailing P/E of 11.9x, gross margin of 82.6%, and ROIC of 47.2%. By comparison, TCMD (Tactile Systems Technology Inc.) holds a C+ grade (67/100 RQD, P/E 28.9x, ROIC 17.1%, cap $521.9M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, MDXG leads on earnings multiple (11.9x) while MDXG leads on capital efficiency (47.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDXG?

▼

Per MDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001376339), MiMedx Group Inc generated $418.6M in revenue (+20.0% YoY), $48.6M in net income, and $74.0M in free cash flow against $342.7M in total assets and $16.5M in total debt. Key quantitative strengths: Strong cash generator (83% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.86 (-0.60%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 17.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDXG)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (69/100 Composite)

🔍 WHY MDXG SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+18/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 17.7% FCF Margin ($74.0M FCF) & 82.6% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$4.69-9.8% Next Q

Q2 (-2Q)

Grade B+$4.23-7.8% Next Q

Q3 (-1Q)

Grade B$3.90-0.5% Next Q

Current

Grade C+$3.88+2% Hist 90D α

Trajectory: B+ (77) → C+ (69)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MDXG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, MDXG faces multiple-compression risk if 11.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 80.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.47) or 200D SMA ($4.26) invalidates the momentum regime and cuts Target Base ($4.07) toward Bear Floor ($3.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDXG• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MDXG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 69%NO 31%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.2% Swing Band

±$0.40 Expected Swing

MODEL EARNINGS SETUP GAUGE

MDXG Quantitative Pre-Earnings Setup: 69/100

Trailing EPS: $0.33 • YoY Revenue Growth: 20%

Model Bullish Setup (69/100)Model Risk Weight (31/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$418.6M	$48.6M	$74.0M	82.6%
FY 2024	2024-12-31	$348.9M	$42.4M	$66.2M	82.8%
FY 2023	2023-12-31	$321.5M	$58.2M	$26.8M	82.6%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating MDXG & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on MDXG
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MDXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.48%📐 HORIZONTAL RANGE

2026-11-03O $3.97H $3.97L $3.88C $3.88VOL 2.12M

RES: $5.32SUP: $3.56SMA50: $4.47SMA200: $4.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDXG Butterfly Map → + Track MDXG →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.3%/yr Implied 5Y Growth

vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MDXG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDXG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MDXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDXG)

Health Care Rank #86 of 1016 ⚔️ TCMD vs MDXG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDXG vs. TCMD, SGHT, ANGO, SENS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MiMedx Group Inc (MDXG) ranks #86 by composite RQD confidence (69/100, grade C+) and #423 by equity capitalization ($566.2M). Within this direct 5-issuer industry benchmark cohort, MDXG leads on earnings valuation at 11.9x trailing P/E, while MDXG leads on capital efficiency and profitability with 47.2% ROIC and 82.6% gross margin. MDXG currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MDXG ACTIVE MiMedx Group Inc	C+	69/100	11.9x	82.6%	47.2%	-2.27%	$566.2M	Benchmark Subject
TCMD Tactile Systems Technology Inc.	C+	67/100	28.9x	75.9%	17.1%	-5.22%	$521.9M	/tcmd-vs-mdxg →
SGHT Sight Sciences Inc.	D-	39/100	—	86.2%	-35.0%	-2.61%	$513.4M	/sght-vs-mdxg →
ANGO AngioDynamics Inc.	D-	36/100	—	54.6%	-23.4%	-2.91%	$504.2M	/ango-vs-mdxg →
SENS Senseonics Holdings Inc.	D-	40/100	—	44.7%	-35.0%	-2.46%	$502.8M	/sens-vs-mdxg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001376339

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MiMedx Group Inc (MDXG) reported GAAP revenue of $418.6M (+20.0% vs. FY2024 revenue of $348.9M , and +30.2% cumulative change since FY2023) , GAAP net income of $48.6M, operating cash flow of $74.0M, and free cash flow of $74.0M (+11.8% YoY). On the balance sheet, MDXG closed FY2025 with $342.7M in total assets against $16.5M in total debt (Altman Z-Score: 6.45, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$418.6M	$48.6M	$74.0M	$74.0M	$342.7M	$16.5M
FY2024 (FY)	2024-12-31	$348.9M	$42.4M	$66.2M	$66.2M	$263.9M	$17.8M
FY2023 (FY)	2023-12-31	$321.5M	$58.2M	$26.8M	$26.8M	—	—

3. MDXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MDXG compare to TCMD and SGHT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MDXG?

Where is MDXG trading relative to its 50-day, 200-day, and 52-week technical levels?

MDXG last traded at $3.88 (-2.27% on volume of 2,124,744 shares), positioning the stock -13.20% below its 50-day simple moving average ($4.47) and -8.92% below its 200-day simple moving average ($4.26). Across its 52-week range of $3.03 to $7.97, MDXG sits at the 17.2% percentile with a 14-day RSI of 35.0 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($3.48 to $4.28).

MDXG Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is MDXG's next earnings date?

Based on SEC filing cadence, MiMedx Group Inc (MDXG)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MDXG stock expected to move on earnings?

Volatility modeling currently projects a ±10.2% event move for MDXG, spanning a range between $3.48 and $4.28.

Direct Sub-Reports: MDXG RQD Cockpit MDXG 12M Forecast MDXG Earnings & Move MDXG Dividends & DRIP MDXG Insiders & 13F MDXG Whale Options MDXG Profit Sankey MDXG News & Why

ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MDXG — MiMedx Group Inc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:34:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 70 / B-, with the verdict "Roarable Buy — Sound Institutional Accumulation" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine: 18 / 20 — references ROIC of 47.2% and FCF yield of 12.77% (per the Roarable RQD rating and market data). A high ROIC and FCF yield are the largest contributors to this pillar's score, suggesting strong capital efficiency and cash generation relative to the stated market value.
Whale 13F Flow: 4 / 20 — the label references institutional accumulation and options positioning, but no 13F holdings or options data are provided in the source data. This is the weakest pillar and provides limited support for the rating.
Insider Conviction: 19 / 20 — the label references SEC Form 4 and Congressional PTR cluster flow (per the Roarable RQD rating). The <holders> section is "NONE," so the underlying trades cannot be independently verified from the supplied data; the score is therefore a rating-level input rather than something traceable here.
Macro Regime Fit: 11 / 20 — references Beta of 1.0 and sector sensitivity (per the Roarable RQD rating and market data). A beta of 1.0 indicates the stock is stated to move in line with the broader market; the score is moderate.
Forensic Balance Sheet: 18 / 20 — references Altman Z-Score of 6.45, Piotroski F-Score of 9/9, and Debt/Equity of 0.06 (per the Roarable RQD rating). These point to a strong stated balance sheet.

For a prospective investor, the rating implies that cash generation, capital efficiency, and balance-sheet strength are the primary supports, while institutional flow evidence is thin. Valuation tradeoffs are visible in the market data: P/E (TTM) of 11.9, Forward P/E of 10, and EV/EBITDA of 6.7 (per the market data). Upside drivers stated in the data center on continued cash flow; the stock's 52-week range of $3.03 - $7.97 with a price of 3.97 places it in the lower portion of that range (per the market data). This analysis is educational and not personalized financial advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
3.97	$579.3M	11.9	10	6.7	0.33	0%	1.0	$3.03 - $7.97	47.2%

Business

MiMedx Group Inc (MDXG) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the company profile). The source data reports gross margin of 82.6%, operating margin of 15.3%, and net margin of 11.6% (per the market data). Customer base, product lines, and revenue mix are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$418.6M	$63.9M	$48.6M	N/A	$74.0M	$166.1M	$16.5M
FY 2024	$348.9M	$58.9M	$42.4M	N/A	$66.2M	$104.4M	$17.8M
FY 2023	$321.5M	$37.1M	$58.2M	N/A	$26.8M	N/A	N/A

Revenue rose from $321.5M (FY 2023) to $418.6M (FY 2025) per the SEC financials. Net income for FY 2023 ($58.2M) exceeds operating income ($37.1M) in the same period; the source data does not explain this. Per the Roarable RQD rating, ROIC is 47.2%, the Altman Z-Score is 6.45, the Piotroski F-Score is 9/9, and Debt/Equity is 0.06. Cash of $166.1M against debt of $16.5M at FY 2025 is consistent with the stated low leverage.

Recent Catalysts & News Wire Analysis

Earnings commentary (YELLOW, MARKET WIRE): Headlines reference Q3 earnings and a profit-question narrative ("MiMedx (MDXG) Stock Slips As Q3 Earnings Leave Profit Questions"; "What MiMedx Group (MDXG) Said on Its Q3 Earnings Call"). Specific Q3 figures are not available in source data.
Sanara merger regulatory risk (RED, RISK WATCH): A headline references a "Fresh Regulatory Obstacle" to the MiMedx-Sanara merger and a related SMTI price drop below support. A companion report (YELLOW, MARKET WIRE) describes the deal spread widening on an FTC second request (per the news wire).
Patent settlement licensing (YELLOW, MARKET WIRE): A headline reports a $25M licensing deal settling a patent dispute. Terms beyond the headline amount are not available in source data.
Market action (YELLOW, MARKET WIRE): A general market-quote report is listed; no additional detail is provided.

The Butterfly graph contains no supply-chain links or proprietary signals (per the Butterfly Supply-Chain Graph).

Open Questions

What were the specific Q3 results and what drove the profit questions referenced in the news wire?
What are the terms and conditions of the Sanara merger, and what is the status of the FTC second request?
What institutional 13F holdings and insider Form 4 transactions underlie the RQD whale and insider pillar scores?
Why does FY 2023 net income ($58.2M) exceed operating income ($37.1M), and what drove the FY 2024–2025 EPS and cash balance trajectory?
What are the terms of the $25M patent licensing settlement and whether it is recurring or one-time?

MDXG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MiMedx Group Inc (MDXG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MDXG Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

MiMedx Group, Inc. (MDXG) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 22h ago

MiMedx (MDXG) Stock Slips As Q3 Earnings Leave Profit Questions

Yahoo Finance report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

What MiMedx Group (MDXG) Said on Its Q3 Earnings Call

TradingView report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stocktwits • 1d ago

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

Stocktwits report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Sanara MedTech/MiMedx deal spread widens on FTC second request (SMTI:NASDAQ)

Seeking Alpha report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

MiMedx (MDXG) Secures $25M Licensing Deal Settling Patent Dispute

GuruFocus report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

MiMedx Group Q3 2026 Earnings Call Transcript

Benzinga report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Wound sales fall 71% at MiMedx (MDXG), even as surgical sales rise.

Stock Titan report covering MiMedx Group Inc (MDXG) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDXG Bull vs. Bear Conversation Board — What's Your Call at $3.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDXG 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $4.68 (+17.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MDXG (B- • RQD 70/100) a Buy at $3.97?

Welcome to the MDXG (MiMedx Group Inc) Roar Pit. Current RQD Composite is 70/100 (Roarable Buy — Sound Institutional Accumulation) in Medical/Dental Instruments. Bulls point to capital efficiency (47.2% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.30 (-16.9%)

Spot @ $3.97

Pump the brakes on MDXG — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MDXG, but look at what you are paying: 11.9x trailing P/E with 82.6% gross margins. Unless MiMedx Group Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.76 (+19.9%)

Spot @ $3.97

MDXG cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MDXG, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $3.97 (52-wk range $3.03 - $7.97), any beat on forward guidance forces shorts and underweight funds to chase.